Global Clinical Chemistry Enzymes Market Set for Steady Growth Projected to Reach USD 5.7 Billion by 2033
Future Market Insights, a leading market intelligence and consulting firm, has released a comprehensive study projecting substantial growth in the global clinical chemistry enzymes market over the next decade. The report forecasts a compound annual growth rate (CAGR) of 5.9%, highlighting a promising trajectory for market expansion.
According to the study, the global clinical chemistry enzymes market was valued at USD 3.1 billion at the end of 2022. By the end of 2023, it is expected to reach USD 3.2 billion, marking a notable 5.3% year-over-year increase. By 2033, the market is anticipated to soar to approximately USD 5.7 billion, indicating sustained growth in the coming years.
Request a Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-17807
Clinical chemistry enzymes play a pivotal role in clinical diagnostics, facilitating the measurement of various analytes crucial for disease diagnosis, monitoring, and research. With the escalating prevalence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer worldwide, the demand for clinical chemistry testing is on the rise. Enzymes serve as indispensable components of diagnostic assays, aiding in the measurement of biomarkers associated with these health conditions, thereby propelling market growth.
As the healthcare landscape continues to evolve and the need for accurate and timely diagnostic solutions intensifies, the global clinical chemistry enzymes market is poised for significant expansion. Manufacturers, healthcare professionals, and stakeholders are anticipated to leverage this growth opportunity to enhance patient care and address the burgeoning demand for diagnostic services worldwide.
Key Takeaways:
- By enzyme type, acid phosphatase – ACP accounts for USD 411.8 million in 2022. Acid phosphatase is commonly used as a biomarker to assess prostate health.
- By application, diagnostics purpose accounts for USD 2.0 Billion in 2022. Clinical chemistry enzymes are essential biomarkers used for the early detection and diagnosis of various diseases and medical conditions
- Hospitals held more than 35.6% of the global market share in 2022. Hospitals handle a large volume of patients for diagnostic testing on a daily basis
- By region, North America held dominant share in world in 2022. The increasing frequency of various liver illnesses will drive market expansion in North America.
Request Customization Available: https://www.futuremarketinsights.com/customization-available/rep-gb-17807
Market Competition:
The clinical chemistry enzymes market is highly competitive, with key players including Thermo Fisher Scientific. These companies are constantly participating conferences, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.
- In September 2021, Thermo Fisher Scientific has announced the availability of their fully automated analyzers, which are intended primarily for applications involving enzyme assays.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the clinical chemistry enzymes market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global clinical chemistry enzymes market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
Key Companies Profiled:
- Takara Bio, Inc.
- Promega Corporation
- Enzo Life Sciences, Inc.
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- Creative Enzyme
- F. Hoffmann-La Roche Ltd.
- Solis BioDyne.
- Ambliqon A/S.
- ekf Diagnostics
- Abbot
- Sekisui Diagnostics
- Aldevron
- Codexis Inc.
Clinical Chemistry Enzymes Market Segmentation:
By Enzyme Type:
- Acid Phosphatase – ACP
- Alanine Amino-Transferase – ALT/GPT
- Alkaline Phosphatase – ALP
- Aspartate Amino-Transferase – AST/GOT
- Cholinesterase – CHE
- Creatine Kinase – CK
- Creatine Kinase MB – CK-MB
- Gamma Glutamyltransferase – GGT
- Glutamate Dehydrogenase – GLDH
- Hydroxybutyrate Dehydrogenase – HBDH
- Lactate Dehydrogenase – LDH
- Lipase – LIP
By Application:
- Diagnostics Purpose
- Therapeutic Purpose
- Analytical purpose
By End User:
- Hospitals
- Diagnostics/Pathology Labs
- Ambulatory Surgical Centers
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Get Complete Full Report: https://www.futuremarketinsights.com/checkout/17807
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
Editor Details
-
Company:
- MARKITWIRED
- Website:
